Webinar: Targeting oxygen sensing in cancer
This webinar from Bio-Techne discusses canonical and alternative oxygen sensing mechanisms implicated in cancer therapy resistance and recurrence.
List view / Grid view
This webinar from Bio-Techne discusses canonical and alternative oxygen sensing mechanisms implicated in cancer therapy resistance and recurrence.
The transparent millifluidic perfusion cassettes (mPCs) developed by researchers should allow for better evaluations of the interactions between the cells and invading pathogens.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
A new study reveals that the healing process following a brain injury could initiate the growth of glioblastoma cancers.
A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.